The stock of BioNTech SE ADR (BNTX) has gone down by -4.78% for the week, with a 2.37% rise in the past month and a -10.36% drop in the past quarter. The volatility ratio for the week is 2.62%, and the volatility levels for the past 30 days are 2.52% for BNTX. The simple moving average for the last 20 days is -4.36% for BNTX stock, with a simple moving average of -14.25% for the last 200 days.
Is It Worth Investing in BioNTech SE ADR (NASDAQ: BNTX) Right Now?
The price-to-earnings ratio for BioNTech SE ADR (NASDAQ: BNTX) is above average at 168.44x. The 36-month beta value for BNTX is also noteworthy at 0.23. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 9 rating it as “hold,” and 2 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BNTX is 237.14M, and at present, short sellers hold a 1.42% of that float. The average trading volume of BNTX on August 01, 2024 was 726.47K shares.
BNTX) stock’s latest price update
BioNTech SE ADR (NASDAQ: BNTX)’s stock price has decreased by -6.46 compared to its previous closing price of 86.20. However, the company has seen a -4.78% decrease in its stock price over the last five trading sessions. reuters.com reported 2024-07-30 that COVID-19 vaccine maker BioNTech’s cancer drug candidate BNT111 showed significant improvement in the response rate in patients with advanced melanoma during a Phase 2 trial, the German company said on Tuesday.
Analysts’ Opinion of BNTX
Many brokerage firms have already submitted their reports for BNTX stocks, with Evercore ISI repeating the rating for BNTX by listing it as a “In-line.” The predicted price for BNTX in the upcoming period, according to Evercore ISI is $100 based on the research report published on May 14, 2024 of the current year 2024.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see BNTX reach a price target of $127. The rating they have provided for BNTX stocks is “Outperform” according to the report published on February 23rd, 2024.
BNTX Trading at -9.66% from the 50-Day Moving Average
After a stumble in the market that brought BNTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.92% of loss for the given period.
Volatility was left at 2.52%, however, over the last 30 days, the volatility rate increased by 2.62%, as shares surge +1.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.21% lower at present.
During the last 5 trading sessions, BNTX fell by -4.14%, which changed the moving average for the period of 200-days by -21.63% in comparison to the 20-day moving average, which settled at $84.37. In addition, BioNTech SE ADR saw -23.60% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BNTX
Current profitability levels for the company are sitting at:
- -0.17 for the present operating margin
- 0.47 for the gross margin
The net margin for BioNTech SE ADR stands at 0.04. The total capital return value is set at -0.02. Equity return is now at value 0.54, with 0.49 for asset returns.
Based on BioNTech SE ADR (BNTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 24.26. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -17.52.
Currently, EBITDA for the company is 1.16 billion with net debt to EBITDA at -158.05. When we switch over and look at the enterprise to sales, we see a ratio of 3.36. The receivables turnover for the company is 1.42for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.38.
Conclusion
In summary, BioNTech SE ADR (BNTX) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
